Hepatic Septal Fibrosis Induced by Long-term Use of Ketoconazole.
- Author:
Jae Wan CHO
1
;
Yoon Ho KO
;
Yong Kyun KIM
;
Young Chul KIM
;
Yong Jick SUNG
;
Si Hyun BAE
;
Jin Il KIM
;
Choon Sang BANG
;
Byung Min AHN
;
Young Min PARK
;
Kyu Won CHUNG
;
Hee Sik SUN
;
Doo Ho PARK
;
Boo Sung KIM
;
Seok Jin KANG
Author Information
1. Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Ketoconazole;
Hepatic septal fibrosis;
Hepatitis/Drug induced
- MeSH:
Fibrosis*;
Hepatitis;
Humans;
Incidence;
Ketoconazole*;
Liver Cirrhosis;
Nausea;
Necrosis;
Plasma;
Vomiting
- From:The Korean Journal of Hepatology
2000;6(2):241-245
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Ketoconazole, an imidazole derivative, is a broad spectrum antifungal agent which has been used widely in the treatment of systemic or local fungal infections. Mild asymptomatic elevation of plasma transaminase activities occurs in approximately 6% to 17.5% of patients who have used ketoconazole. However, the incidence of symptomatic hepatic injury is low and overt hepatitis develops in about 5% of the patients. Nausea and vomiting are the most frequent side reactions. Histopathological features of the reported ketoconazole induced hepatotoxicity are massive or submassive hepatocellular necrosis involving the acinar zone 3, destroyed lobular architecture with bridging necrosis and inflammatory cell infiltration on portal tracts. However, hepatic septal fibrosis with liver cirrhosis has not been reported yet. We experienced a case of hepatic septal fibrosis that developed after 9 months of ketoconazole administration.
